Intranasal Ketamine
Phase 3Small molecule
Intranasal Ketamine is one of 60 small molecule programs targeting Sedation. It is currently in Phase 3.
3
Indications
29
Total Trials
5
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
55 competitors in Children
#DrugCompanyPhaseTrials
1Promacta
GSKApproved
Gleevec
NovartisApproved
Oncaspar
SServier
Approved
Sprycel
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Velcade
SShilpa Grover, MD, MPH
Approved
Byetta
AstraZenecaPhase 3
Neurontin
VViatris Specialty LLC
Phase 3
Somavaratan
Novo NordiskPhase 3
Veklury
GileadPhase 2
Xyrem
Jazz PharmaceuticalsPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation4 trials
Children2 trials
Nerve Block1 trial
20 more indications
Buprenorphine1 trial
Drug Interactions1 trial
Alcohol Abuse1 trial
Dexmedetomidine1 trial
Pilot Study1 trial
Sickle Cell Disease1 trial
Safety and Efficacy1 trial
Treatment Resistant Depression1 trial
Depressive Disorder1 trial
Major Depressive Disorder1 trial
Randomized Controlled Trial1 trial
Unspecified1 trial
INK Feasibility Study
Withdrawn·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 3·NCT05783492
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intranasal Ketamine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- JJavelin Pharmaceuticals